Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oculis Holding AG (OCS) Amortizatization of Intangibles (2022 - 2024)

Quarterly Amortizatization of Intangibles rose 66.52% to $50410.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $201003.6 through Mar 2024, changed N/A year-over-year, with the annual reading at $182631.4 for FY2023, 5.35% up from the prior year.

Oculis Holding AG's Amortizatization of Intangibles history spans 3 years, with the latest figure at $50410.0 for Q1 2024.

  • Amortizatization of Intangibles came in at $50410.0 for Q1 2024, down from $50731.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $50731.0 in Q4 2023 to a low of $30272.6 in Q1 2023.
  • The 3-year median for Amortizatization of Intangibles is $49814.7 (2023), against an average of $45629.0.
  • Year-over-year, Amortizatization of Intangibles rose 11.07% in 2023 and then surged 66.52% in 2024.
  • Oculis Holding AG's Amortizatization of Intangibles stood at $45673.0 in 2022, then increased by 11.07% to $50731.0 in 2023, then decreased by 0.63% to $50410.0 in 2024.
  • Per Business Quant, the three most recent readings for OCS's Amortizatization of Intangibles are $50410.0 (Q1 2024), $50731.0 (Q4 2023), and $49814.7 (Q3 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 13,267.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 50,410.02
Mar 31, 2024 50,410.02
Dec 31, 2023 50,730.95
Dec 31, 2023 50,730.95
Sep 30, 2023 49,814.71
Sep 30, 2023 49,814.71
Jun 30, 2023 50,047.90
Jun 30, 2023 50,047.90
Mar 31, 2023 30,272.55
Mar 31, 2023 30,272.55
Dec 31, 2022 45,672.96
Dec 31, 2022 45,672.96
Sep 30, 2022 42,453.72
Sep 30, 2022 42,453.72